
Today GRAIL reported third quarter 2026 financial results. Read the press release: bit.ly/3UuTlDq

GRAIL's mission is to detect cancer early, when it can be cured. Community Guidelines: bit.ly/3xigb24 Cancer SIGNAL Podcast: grail.com/podcast/

Today GRAIL reported third quarter 2026 financial results. Read the press release: bit.ly/3UuTlDq

We will report third quarter 2026 financial results on November 4. Register for the webcast: bit.ly/4siXcj9 Read more: bit.ly/4k89d94

We’re looking forward to presenting several abstracts at EDCC and #ESMO26 that highlight advances in multi-cancer early detection, spanning clinical performance, health equity, real-world implementation, and the cancer diagnostic journey. Learn more: bit.ly/4hEXBJn

Today GRAIL announced a favorable vote from an FDA Advisory Committee for the approval of the Premarket Approval application of the Galleri multi-cancer early detection test (MCED). The Committee considered Galleri’s safety, effectiveness, and overall benefit-risk profile for screening for the early detection of multiple types of cancer in adults aged 50 years and older. Read more: bit.ly/4rpmwUd #MCED #Galleri #CancerScreening

Full cohort results from GRAIL’s PATHFINDER 2 study have been published in @NatureMedicine, adding to the growing body of evidence supporting multi-cancer early detection (MCED) testing. Learn more: bit.ly/4y3psIK Rx Only. See Important Safety Information: bit.ly/411L6zk

Detailed peer-reviewed results from the NHS-Galleri trial are now published in @NEJM and @NatureMedicine, providing clinical utility and performance data. These results reflect GRAIL’s commitment to setting a high bar for MCED evidence—rigorously demonstrating Galleri’s potential to reduce late-stage diagnoses and find more cancers earlier. #EarlyCancerDetection #CancerScreening #MCED Learn more: New England Journal of Medicine: bit.ly/3Vbd5f8 Nature Medicine: bit.ly/4y9il1j Rx Only. See Important Safety Information: bit.ly/411L6zk


Today GRAIL announced that the U.S. Food and Drug Administration’s (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on Sept. 23, 2026 to review the Premarket Approval (PMA) application for the Galleri® multi-cancer early detection (MCED) blood test. Learn more: bit.ly/4hV1Lgs

Today GRAIL reported second quarter 2026 financial results. Read the press release: bit.ly/4pZIRXX

We will announce second quarter 2026 financial results on August 5. Register for the webcast: bit.ly/3RoDKUq Read more: bit.ly/4pJMG3g

Today announced a collaboration with Priority Health, a nationally recognized nonprofit health plan and the third largest provider-sponsored health plan in the nation to make GRAIL’s Galleri multi-cancer early detection (MCED) test available to Priority Health’s self-insured employer groups. Learn more: bit.ly/3TklThO #MCED #EarlyCancerDetection

Many cancers stay hidden until it is too late. When cancer is diagnosed after it has spread distantly, it is more difficult to treat and typically has worse outcomes. Diagnosing cancer before Stage IV can make a meaningful difference. For a growing number of cancers, treatment with curative intent may still be possible at Stage III. That’s why reducing Stage IV diagnoses remains such an important part of improving cancer outcomes. Learn more: grail.com #CancerScreening #EarlyCancerDetection

Today GRAIL announced the closing of its previously announced equity financing with Samsung affiliates including Samsung C&T Corporation. Learn more: bit.ly/3StlF7I

Melissa didn’t take a multi-cancer early detection (MCED) test once and leave it at that. She made MCED testing part of her annual health routine. The first year, the test did not detect a cancer signal. The second year, she received a Cancer Signal Detected result with a predicted origin of liver/bile ducts. Melissa felt healthy and had no symptoms. Follow up diagnostic testing confirmed Stage I bile duct cancer. Now she’s using her story to encourage others to keep cancer screening part of the conversation, year after year. #CancerScreening #EarlyCancerDetection #MCED The overall sensitivity in study participants with liver/bile duct cancer was 93.5% (100% for stage I, 70.0% stage II, 100% stage III, 100% stage IV). Rx only. See Important Safety Information: galleri.com/safety-informati…

“Early detection can save an awful lot of lives, I think I’m evidence of that.” Ann joined the NHS-Galleri trial evaluating a multi-cancer early detection (MCED) test hoping her participation might help others. She never imagined it would help her, too. Watch her story and learn more about the NHS-Galleri trial: bit.ly/4wY05Ij The overall sensitivity in study participants with colon/rectum cancer was 82% (43.3% for stage I, 85% stage II, 87.9% stage III, 95.3% stage IV).

Robert signed on for the NHS-Galleri trial with the intention of advancing cancer research. When the multi-cancer early detection (MCED) test returned a Cancer Signal Detected result, he was shocked. On the latest episode of The Cancer SIGNAL podcast, host Rayshawnda Madison speaks with Robert as he shares how his follow-up journey eventually led to an early HPV-related cancer diagnosis, what it was like to navigate treatment and recovery, and how the experience changed the way he thinks about health and early detection. The Cancer SIGNAL is available wherever you listen to podcasts. #EarlyCancerDetection #MCED #Podcast Apple Podcasts: bit.ly/4byN5jM Spotify: bit.ly/4bOp9I4 Transcripts & more episodes: grail.com/podcast/